Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

REFERENCES

• Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E. Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A.; Swain, S.M.; Pisansky, T.M.; Fehrenbacher, L.; Kutteh, L.A.; Vogel, V.G.; Visscher, D.W.; Yothers, G.; Jenkins, R.B.; Brown, A.M.; Dakhil, S.R.; Mamounas, E.P.; Lingle, W.L.; Klein, P.M.; Ingle, J.N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353, 1673–1684.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart, M.J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C.; Cameron, D.; Dowsett, M.; Barrios, C.H.; Steger, G.; Huang, C.S.; Andersson, M.; Inbar, M.; Lichinitser, M.; Láng, I.; Nitz, U.; Iwata, H.; Thomssen, C.; Lohrisch, C.; Suter, T.M.; Rüschoff, J.; Suto, T.; Greatorex, V.; Ward, C.; Straehle, C.; McFadden, E.; Dolci, M.S.; Gelber, R.D; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353, 1659–1672.
   PubMed Web of Science ®Google Scholar
• Borg, A.; Tandon, A.K.; Sigurdsson, H.; Clark, G.M.; Ferno, M.; Fuqua, S.A.; Killander, D.; McGuire, W.L. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990, 50, 4332–4337.
   PubMed Web of Science ®Google Scholar
• Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177–182.
   PubMed Web of Science ®Google Scholar
• Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; Press, M.F Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707–712.
   PubMed Web of Science ®Google Scholar
• Gusterson, B.A.; Gelber, R.D.; Goldhirsch, A.; Price, K.N.; Säve-Söderborgh, J.; Anbazhagan, R.; Styles, J.; Rudenstam, C.M.; Golouh, R.; Reed, R.; Martinez-Tello, F.; Tiltman, A.; Torhorst, J.; Grigolato, P.; Bettelheim, R.; Neville, A.M.; Birki, K.; Castiglione, Collins, M.J.; Lindtner, J. Prognostic importance of c-erbB 2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992, 10, 1049–1056.
   PubMed Web of Science ®Google Scholar
• Stark, A.T.; Claud, S.; Kapke, A.; Lu, M.; Linden, M.; Griggs, J. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. Cancer 2005, 104, 2189–2196.
   PubMed Web of Science ®Google Scholar
• Huang, H.J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Christiaens, M.R.; Vergote, I. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005, 91, 81–87.
   PubMed Web of Science ®Google Scholar
• Huang, H.J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Vergote, I.; Christiaens, MR. Association between tumour characteristics and HER-2/neu by immunohistochemisrty in 1362 women with primary operable breast cancer. J Clin Pathol 2005, 58, 611–616.
   PubMed Web of Science ®Google Scholar
• Huang, H.J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Vergote, I.; Christiaens, M.R. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005, 16, 1755–1761.
   PubMed Web of Science ®Google Scholar
• Konecny, G.; Pauletti, G.; Pegram, M.; Untch, M.; Dandekar, S.; Aguilar, Z.; Wilson, C.; Rong, H.M.; Bauerfeind, I.; Felber, M.; Wang, HJ.; Beryt, M.; Seshadri, R.; Hepp, H.; Slamon, DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95, 142–153.
   PubMed Web of Science ®Google Scholar
• Carey, LA.; Perou, CM.; Livasy, CA.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; Deming, S.L.; Geradts, J.; Cheang, M.C.; Nielsen, TO.; Moorman, P.G.; Earp, H.S.; Millikan, RC. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295, 2492–2502.
   PubMed Web of Science ®Google Scholar
• Anderson, W.F.; Luo, S.; Chatterjee, N.; Rosenberg, P.S.; Matsuno, R.K.; Goodman, M.T.; et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 2009, 113, 189–196.
   PubMed Web of Science ®Google Scholar
• SAS Institute Inc. SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute Inc, 2004.
   Google Scholar
• Paik, S.; Bryant, J.; Tan-Chiu, E.; Romond, E.; Hiller, W.; Park, K.; et al. Real-world performance of HER2 testing –National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002, 94, 852–854.
   PubMed Web of Science ®Google Scholar
• Perez, EA.; Suman, VJ.; Davidson, N.E.; Martino, S.; Kaufman, P.A.; Lingle, W.L.; Flynn, P.J.; Ingle, J.N.; Visscher, D.; Jenkins, R.B. HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24, 3032–3038.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society, 2006.
   Google Scholar